Amphotericin B Liposome + AmBisome (Amphotericin B) Liposome
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visceral Leishmaniasis
Conditions
Visceral Leishmaniasis
Trial Timeline
May 2, 2018 → Apr 5, 2019
NCT ID
NCT03636659About Amphotericin B Liposome + AmBisome (Amphotericin B) Liposome
Amphotericin B Liposome + AmBisome (Amphotericin B) Liposome is a phase 1 stage product being developed by Aurobindo Pharma for Visceral Leishmaniasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03636659. Target conditions include Visceral Leishmaniasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03636659 | Phase 1 | Completed |
Competing Products
5 competing products in Visceral Leishmaniasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LXE408 + AmBisome® | Novartis | Phase 2 | 52 |
| LXE408 + sodium stibogluconate + Paromomycin | Novartis | Phase 2 | 52 |
| Liposomal amphotericin B (AmBisome®) and sodium stibogluconate + Liposomal amphotericin B + miltefosine + Miltefosine | Gilead Sciences | Phase 2 | 51 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Rifaximin | Bausch Health | Phase 2 | 47 |
Other Products from Aurobindo Pharma
Test Product + Reference Product + PlaceboPhase 3
77
Adapalene 0.1% Gel + Differin 0.1% Topical GelPhase 3
77
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboPhase 3
77
Amlodipine - reference + Amlodipine ODT - test + Amlodipine ODT - testPhase 1
33
Amlodipine - reference + Amlodipine ODT - testPhase 1
33